Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CTI Finds Pixuvri’s Conditional Authorization Is Not Enough To Win NICE Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

In an early stage decision, NICE rejects Pixuvri for multiply relapsed or refractory aggressive non-Hodgkin's lymphoma, citing lack of evidence and cost-effectiveness.

You may also be interested in...

NICE On Alimta, Pixuvri Ups Concerns It Prefers Cost Over Clinical Efficacy

NICE’s tentative nod to CTI’s Pixuvri for NHL and refusal to grant an indication extension to Lilly’s Alimta could spark industry concern that the agency favors lower cost over clinical effectiveness.

CTI’s Pixuvri Flops Again At British NICE, As Discount Fails To Impress

Despite a sizeable price cut, uncertainty surrounding CTI’s non-Hodgkin’s lymphoma therapy Pixuvri has landed it with a second NICE rejection.

Germany’s G-BA Finds No Added Benefit For CTI’s Pixuvri, Exposing Price

Germany’s G-BA lets through Cell Therapeutics’ Pixuvri for aggressive B-cell non-Hodgkin's lymphoma but finds no added benefit over existing therapies, meaning its price could come under pressure.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts